New topline Phase I/II data show that an allogeneic cell therapy could help restore vision in individuals with corneal oedema secondary to corneal endothelial dysfunction. AURN001 combines allogeneic human corneal endothelial cells (neltependocel) and a rho kinase inhibitor (Y-27632).
The CLARA Phase I/II clinical trial evaluated the safety, tolerability, and efficacy the allogeneic cell therapy product candidate at sites in the US and Canada.